High-intensity focused ultrasound (HIFU) has shown promise as a pain management strategy in patients with bone metastases for whom other treatments are ineffective, according to researchers at the Sheba Medical Center in Israel (Ann Oncol 2007;18:163-167).
High-intensity focused ultrasound (HIFU) has shown promise as a pain management strategy in patients with bone metastases for whom other treatments are ineffective, according to researchers at the Sheba Medical Center in Israel (Ann Oncol 2007;18:163-167).
The goal of treatment for bone metastases is to relieve pain and reduce the risk of fracture. Treatment may consist of surgery, radiation therapy, pain medications, and/or bisphosphonate drugs.
In the study, 10 patients reported prolonged improvement in pain and/or a reduced dose of pain medication following MR-guided ultrasound ablation of bone metastases. One other patient found the MR-guided HIFU procedure too uncomfortable to complete treatment.
MR-guided HIFU is approved in the U.S. only for uterine fibroids, but researchers are investigating applications in breast, prostate, and brain tumors.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.